InvestorsHub Logo
Followers 115
Posts 20074
Boards Moderated 0
Alias Born 06/13/2011

Re: None

Thursday, 09/24/2020 11:08:21 AM

Thursday, September 24, 2020 11:08:21 AM

Post# of 422604
AMRN expects to be granted 10 yrs marketing exclusivity on approval in the EU .

Is this a reasonable expectation . Can anyone argue why they shouldn't receive this marketing exclusivity ?
I believe its a new treatment exclusivity but will chk .

https://www.ema.europa.eu/en/documents/presentation/presentation-data-exclusivity-market-protection-orphan-paediatric-rewards-s-ribeiro_en.pdf

Market protection
= Period of time during which a generic, hybrid or biosimilar cannot be placed on the market, even if the medicinal product has already received a marketing authorisation



The EU market potential is the only reason to own or consider buying AMRN at these levels IMHO
Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News